Pathogenetic development, diagnosis and clinical therapeutic approaches for liver metastasis from colorectal cancer (Review)

Singh S, Gomez HJ, Thakkar S, Singh SP and Parihar AS: Overcoming acquired drug resistance to cancer therapies through targeted STAT3 inhibition. Int J Mol Sci. 24:47222023. View Article : Google Scholar : PubMed/NCBI

Yoshino T, Portnoy DC, Obermannová R, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, García-Alfonso P, Cohn AL, Van Cutsem E, et al: Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study. Ann Oncol. 30:124–131. 2019. View Article : Google Scholar

Stewart CL, Warner S, Ito K, Raoof M, Wu GX, Kessler J, Kim JY and Fong Y: Cytoreduction for colorectal metastases: Liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure? Curr Probl Surg. 55:330–379. 2018. View Article : Google Scholar : PubMed/NCBI

Norén A, Sandström P, Gunnarsdottir K, Ardnor B, Isaksson B, Lindell G and Rizell M: Identification of inequalities in the selection of liver surgery for colorectal liver metastases in sweden. Scand J Surg. 107:294–301. 2018. View Article : Google Scholar : PubMed/NCBI

Margonis GA, Sergentanis TN, Ntanasis-Stathopoulos I, Andreatos N, Tzanninis IG, Sasaki K, Psaltopoulou T, Wang J, Buettner S, Papalois ΑE, et al: Impact of surgical margin width on recurrence and overall survival following R0 hepatic resection of colorectal metastases: A systematic review and Meta-analysis. Ann Surg. 267:1047–1055. 2018. View Article : Google Scholar

Qin S, Liu GJ, Huang M, Huang J, Luo Y, Wen Y, Wang Y and Chen L: The local efficacy and influencing factors of ultrasound-guided percutaneous microwave ablation in colorectal liver metastases: A review of a 4-year experience at a single center. Int J Hyperthermia. 36:36–43. 2019. View Article : Google Scholar

Paget S: The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8:98–101. 1989.PubMed/NCBI

Peña C, García JM, Silva J, García V, Rodríguez R, Alonso I, Millán I, Salas C, de Herreros AG, Muñoz A and Bonilla F: E-cadherin and vitamin D receptor regulation by SNAIL and ZEB1 in colon cancer: Clinicopathological correlations. Hum Mol Genet. 14:3361–3370. 2005. View Article : Google Scholar : PubMed/NCBI

He X, Chen Z, Jia M and Zhao X: Downregulated E-cadherin expression indicates worse prognosis in Asian patients with colorectal cancer: Evidence from meta-analysis. PLoS One. 8:e708582013. View Article : Google Scholar : PubMed/NCBI

Toiyama Y, Yasuda H, Saigusa S, Tanaka K, Inoue Y, Goel A and Kusunoki M: Increased expression of Slug and Vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis. 34:2548–2557. 2013. View Article : Google Scholar : PubMed/NCBI

Oh BY, Hong HK, Lee WY and Cho YB: Animal models of colorectal cancer with liver metastasis. Cancer Lett. 387:114–120. 2017. View Article : Google Scholar

Helling TS and Martin M: Cause of death from liver metastases in colorectal cancer. Ann Surg Oncol. 21:501–506. 2014. View Article : Google Scholar

Tsilimigras DI, Hyer JM, Bagante F, Guglielmi A, Ruzzenente A, Alexandrescu S, Poultsides G, Sasaki K, Aucejo F and Pawlik TM: Resection of colorectal liver metastasis: Prognostic impact of tumor burden vs KRAS mutational status. J Am Coll Surg. 232:590–598. 2021. View Article : Google Scholar : PubMed/NCBI

Tsilimigras DI, Brodt P, Clavien PA, Muschel RJ, D'Angelica MI, Endo I, Parks RW, Doyle M, de Santibañes E and Pawlik TM: Liver metastases. Nat Rev Dis Primers. 7:272021. View Article : Google Scholar : PubMed/NCBI

Tsilimigras DI, Ntanasis-Stathopoulos I, Bagante F, Moris D, Cloyd J, Spartalis E and Pawlik TM: Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. Surg Oncol. 27:280–288. 2018. View Article : Google Scholar : PubMed/NCBI

Zhou H, Liu Z, Wang Y, Wen X, Amador EH, Yuan L, Ran X, Xiong L, Ran Y, Chen W and Wen Y: Colorectal liver metastasis: Molecular mechanism and interventional therapy. Signal Transduct Target Ther. 7:702022. View Article : Google Scholar : PubMed/NCBI

Yuzhalin AE and Yu D: Brain metastasis organotropism. Cold Spring Harb Perspect Med. 10:a0372422020. View Article : Google Scholar

Mielgo A and Schmid MC: Liver tropism in cancer: The hepatic metastatic niche. Cold Spring Harb Perspect Med. 10:a0372592020. View Article : Google Scholar

Yoon H, Sabate Del Rio J, Cho SW and Park TE: Recent advances in micro-physiological systems for investigating tumor metastasis and organotropism. Lab Chip. 24:1351–1366. 2024. View Article : Google Scholar : PubMed/NCBI

Milette S, Sicklick JK, Lowy AM and Brodt P: Molecular pathways: Targeting the microenvironment of liver metastases. Clin Cancer Res. 23:6390–6399. 2017. View Article : Google Scholar : PubMed/NCBI

Elsayes KM, Shaaban AM, Rothan SM, Javadi S, Madrazo BL, Castillo RP, Casillas VJ and Menias CO: A comprehensive approach to hepatic vascular disease. Radiographics. 37:813–836. 2017. View Article : Google Scholar : PubMed/NCBI

Wang X, Huang S, Lu X, Huang Y and Chi P: Incidence of and risk factors for gastroepiploic lymph node involvement in patients with cancer of the transverse colon including the hepatic flexure. World J Surg. 45:1514–1525. 2021. View Article : Google Scholar : PubMed/NCBI

Poisson J, Lemoinne S, Boulanger C, Durand F, Moreau R, Valla D and Rautou PE: Liver sinusoidal endothelial cells: Physiology and role in liver diseases. J Hepatol. 66:212–227. 2017. View Article : Google Scholar

Zheng M and Tian Z: Liver-mediated adaptive immune tolerance. Front Immunol. 10:25252019. View Article : Google Scholar : PubMed/NCBI

Heymann F, Peusquens J, Ludwig-Portugall I, Kohlhepp M, Ergen C, Niemietz P, Martin C, van Rooijen N, Ochando JC, Randolph GJ, et al: Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology. 62:279–291. 2015. View Article : Google Scholar : PubMed/NCBI

Wang D, Wang X, Si M, Yang J, Sun S, Wu H, Cui S, Qu X and Yu X: Exosome-encapsulated miRNAs contribute to CXCL12/CXCR4-induced liver metastasis of colorectal cancer by enhancing M2 polarization of macrophages. Cancer Lett. 474:36–52. 2020. View Article : Google Scholar : PubMed/NCBI

Feng W, Huang W, Chen J, Qiao C, Liu D, Ji X, Xie M, Zhang T, Wang Y, Sun M, et al: CXCL12-mediated HOXB5 overexpression facilitates Colorectal Cancer metastasis through transactivating CXCR4 and ITGB3. Theranostics. 11:2612–2633. 2021. View Article : Google Scholar : PubMed/NCBI

Zhao S, Mi Y, Zheng B, Wei P, Gu Y, Zhang Z, Xu Y, Cai S, Li X and Li D: Highly-metastatic colorectal cancer cell released miR-181a-5p-rich extracellular vesicles promote liver metastasis by activating hepatic stellate cells and remodelling the tumour microenvironment. J Extracell Vesicles. 11:e121862022. View Article : Google Scholar : PubMed/NCBI

Lamouille S, Xu J and Derynck R: Molecular mechanisms of Epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI

Ang HL, Mohan CD, Shanmugam MK, Leong HC, Makvandi P, Rangappa KS, Bishayee A, Kumar AP and Sethi G: Mechanism of epithelial-mesenchymal transition in cancer and its regulation by natural compounds. Med Res Rev. 43:1141–1200. 2023. View Article : Google Scholar : PubMed/NCBI

Jayachandran J, Srinivasan H and Mani KP: Molecular mechanism involved in epithelial to mesenchymal transition. Arch Biochem Biophys. 710:1089842021. View Article : Google Scholar : PubMed/NCBI

Cho ES, Kang HE, Kim NH and Yook JI: Therapeutic implications of cancer epithelial-mesenchymal transition (EMT). Arch Pharm Res. 42:14–24. 2019. View Article : Google Scholar : PubMed/NCBI

Zhang N, Ng AS, Cai S, Li Q, Yang L and Kerr D: Novel therapeutic strategies: Targeting epithelial-mesenchymal transition in colorectal cancer. Lancet Oncol. 22:e358–e368. 2021. View Article : Google Scholar : PubMed/NCBI

Kulus M, Farzaneh M, Bryja A, Zehtabi M, Azizidoost S, Abouali Gale Dari M, Golcar-Narenji A, Ziemak H, Chwarzyński M, Piotrowska-Kempisty H, et al: Phenotypic transitions the processes involved in regulation of growth and proangiogenic properties of stem cells, cancer stem cells and circulating tumor cells. Stem Cell Rev Rep. 20:967–979. 2024. View Article : Google Scholar : PubMed/NCBI

Akhurst RJ: From shape-shifting embryonic cells to oncology: The fascinating history of epithelial mesenchymal transition. Semin Cancer Biol. 96:100–114. 2023. View Article : Google Scholar : PubMed/NCBI

Zhou S, Xu H, Duan Y, Tang Q, Huang H and Bi F: Survival mechanisms of circulating tumor cells and their implications for cancer treatment. Cancer Metastasis Rev. 43:941–957. 2024. View Article : Google Scholar : PubMed/NCBI

Xie Q, Liu S, Zhang S, Liao L, Xiao Z, Wang S and Zhang P: Research progress on the multi-omics and survival status of circulating tumor cells. Clin Exp Med. 24:492024. View Article : Google Scholar : PubMed/NCBI

Gkountela S, Castro-Giner F, Szczerba BM, Vetter M, Landin J, Scherrer R, Krol I, Scheidmann MC, Beisel C, Stirnimann CU, et al: Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell. 176:98–112.e14. 2019. View Article : Google Scholar : PubMed/NCBI

Rozenberg JM, Buzdin AA, Mohammad T, Rakitina OA, Didych DA, Pleshkan VV and Alekseenko IV: Molecules promoting circulating clusters of cancer cells suggest novel therapeutic targets for treatment of metastatic cancers. Front Immunol. 14:10999212023. View Article : Google Scholar : PubMed/NCBI

Hou JM, Krebs M, Ward T, Sloane R, Priest L, Hughes A, Clack G, Ranson M, Blackhall F and Dive C: Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol. 178:989–996. 2011. View Article : Google Scholar : PubMed/NCBI

Francescangeli F, Magri V, De Angelis ML, De Renzi G, Gandini O, Zeuner A, Gazzaniga P and Nicolazzo C: Sequential isolation and characterization of single CTCs and large CTC clusters in metastatic colorectal cancer patients. Cancers (Basel). 13:63622021. View Article : Google Scholar : PubMed/NCBI

Leblanc R and Peyruchaud O: Metastasis: New functional implications of platelets and megakaryocytes. Blood. 128:24–31. 2016. View Article : Google Scholar : PubMed/NCBI

Plantureux L, Mège D, Crescence L, Carminita E, Robert S, Cointe S, Brouilly N, Ezzedine W, Dignat-George F, Dubois C and Panicot-Dubois L: The Interaction of platelets with colorectal cancer cells inhibits tumor growth but promotes metastasis. Cancer Res. 80:291–303. 2020. View Article : Google Scholar

Szczerba BM, Castro-Giner F, Vetter M, Krol I, Gkountela S, Landin J, Scheidmann MC, Donato C, Scherrer R, Singer J, et al: Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature. 566:553–557. 2019. View Article : Google Scholar : PubMed/NCBI

Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D and Jain RK: Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci USA. 107:21677–21682. 2010. View Article : Google Scholar : PubMed/NCBI

Ormseth B, Onuma A, Zhang H and Tsung A: The hepatic Pre-metastatic niche. Cancers (Basel). 14:37312022. View Article : Google Scholar : PubMed/NCBI

Trefts E, Gannon M and Wasserman DH: The liver. Curr Biol. 27:R1147–R1151. 2017. View Article : Google Scholar : PubMed/NCBI

Li X, Ramadori P, Pfister D, Seehawer M, Zender L and Heikenwalder M: The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer. 21:541–557. 2021. View Article : Google Scholar : PubMed/NCBI

Gong J, Tu W, Liu J and Tian D: Hepatocytes: A key role in liver inflammation. Front Immunol. 13:10837802022. View Article : Google Scholar

Carvalho-Gontijo R, Han C, Zhang L, Zhang V, Hosseini M, Mekeel K, Schnabl B, Loomba R, Karin M, Brenner DA and Kisseleva T: Metabolic injury of hepatocytes promotes progression of NAFLD and AALD. Semin Liver Dis. 42:233–249. 2022. View Article : Google Scholar : PubMed/NCBI

Rigual MDM, Sanchez Sanchez P and Djouder N: Is liver regeneration key in hepatocellular carcinoma development? Trends Cancer. 9:140–157. 2023. View Article : Google Scholar

Amilca-Seba K, Sabbah M, Larsen AK and Denis JA: Osteopontin as a regulator of colorectal cancer progression and its clinical applications. Cancers (Basel). 13:37932021. View Article : Google Scholar : PubMed/NCBI

Li JJ, Wang JH, Tian T, Liu J, Zheng YQ, Mo HY, Sheng H, Chen YX, Wu QN, Han Y, et al: The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer. Nat Commun. 14:66902023. View Article : Google Scholar : PubMed/NCBI

Pandey E, Nour AS and Harris EN: Prominent receptors of liver sinusoidal endothelial cells in liver homeostasis and disease. Front Physiol. 11:8732020. View Article : Google Scholar : PubMed/NCBI

Szafranska K, Kruse LD, Holte CF, McCourt P and Zapotoczny B: The wHole story about fenestrations in LSEC. Front Physiol. 12:7355732021. View Article : Google Scholar : PubMed/NCBI

Xu GX, Wei S, Yu C, Zhao SQ, Yang WJ, Feng YH, Pan C, Yang KX and Ma Y: Activation of Kupffer cells in NAFLD and NASH: Mechanisms and therapeutic interventions. Front Cell Dev Biol. 11:11995192023. View Article : Google Scholar : PubMed/NCBI

Li W, Chang N and Li L: Heterogeneity and function of kupffer cells in liver injury. Front Immunol. 13:9408672022. View Article : Google Scholar : PubMed/NCBI

Kubes P and Jenne C: Immune responses in the liver. Annu Rev Immunol. 36:247–277. 2018. View Article : Google Scholar : PubMed/NCBI

Matsumura H, Kondo T, Ogawa K, Tamura T, Fukunaga K, Murata S and Ohkohchi N: Kupffer cells decrease metastasis of colon cancer cells to the liver in the early stage. Int J Oncol. 45:2303–2310. 2014. View Article : Google Scholar : PubMed/NCBI

Williamson T, Sultanpuram N and Sendi H: The role of liver microenvironment in hepatic metastasis. Clin Transl Med. 8:212019. View Article : Google Scholar : PubMed/NCBI

Keirsse J, Van Damme H, Geeraerts X, Beschin A, Raes G and Van Ginderachter JA: The role of hepatic macrophages in liver metastasis. Cell Immunol. 330:202–215. 2018. View Article : Google Scholar : PubMed/NCBI

Yang M and Zhang C: The role of liver sinusoidal endothelial cells in cancer liver metastasis. Am J Cancer Res. 11:1845–1860. 2021.PubMed/NCBI

Ou J, Peng Y, Deng J, Miao H, Zhou J, Zha L, Zhou R, Yu L, Shi H and Liang H: Endothelial cell-derived fibronectin extra domain A promotes colorectal cancer metastasis via inducing epithelial-mesenchymal transition. Carcinogenesis. 35:1661–1670. 2014. View Article : Google Scholar : PubMed/NCBI

Ciner AT, Jones K, Muschel RJ and Brodt P: The unique immune microenvironment of liver metastases: Challenges and opportunities. Semin Cancer Biol. 71:143–156. 2021. View Article : Google Scholar

Yu X, Chen L, Liu J, Dai B, Xu G, Shen G, Luo Q and Zhang Z: Immune modulation of liver sinusoidal endothelial cells by melittin nanoparticles suppresses liver metastasis. Nat Commun. 10:5742019. View Article : Google Scholar : PubMed/NCBI

Crispe IN: The liver as a lymphoid organ. Annu Rev Immunol. 27:147–163. 2009. View Article : Google Scholar : PubMed/NCBI

Prager I, Liesche C, van Ooijen H, Urlaub D, Verron Q, Sandström N, Fasbender F, Claus M, Eils R, Beaudouin J, et al: NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing. J Exp Med. 216:2113–2127. 2019. View Article : Google Scholar : PubMed/NCBI

Shimasaki N, Jain A and Campana D: NK cells for cancer immunotherapy. Nat Rev Drug Discov. 19:200–218. 2020. View Article : Google Scholar : PubMed/NCBI

Wiltrout RH: Regulation and antimetastatic functions of liver-associated natural killer cells. Immunol Rev. 174:63–76. 2000. View Article : Google Scholar : PubMed/NCBI

Lopez-Soto A, Gonzalez S, Smyth MJ and Galluzzi L: Control of Metastasis by NK Cells. Cancer Cell. 32:135–154. 2017. View Article : Google Scholar : PubMed/NCBI

Donadon M, Hudspeth K, Cimino M, Di Tommaso L, Preti M, Tentorio P, Roncalli M, Mavilio D and Torzilli G: Increased infiltration of natural killer and T cells in colorectal liver metastases improves patient overall survival. J Gastrointest Surg. 21:1226–1236. 2017. View Article : Google Scholar : PubMed/NCBI

Harmon C, Robinson MW, Hand F, Almuaili D, Mentor K, Houlihan DD, Hoti E, Lynch L, Geoghegan J and O'Farrelly C: Lactate-mediated acidification of tumor microenvironment induces apoptosis of Liver-resident NK cells in colorectal liver metastasis. Cancer Immunol Res. 7:335–346. 2019. View Article : Google Scholar

Stiff A, Trikha P, Mundy-Bosse B, McMichael E, Mace TA, Benner B, Kendra K, Campbell A, Gautam S, Abood D, et al: Nitric oxide production by Myeloid-derived suppressor cells plays a role in impairing Fc Receptor-mediated natural killer cell function. Clin Cancer Res. 24:1891–1904. 2018. View Article : Google Scholar : PubMed/NCBI

Song J, Song H, Wei H, Sun R, Tian Z and Peng H: Requirement of RORα for maintenance and antitumor immunity of liver-resident natural killer cells/ILC1s. Hepatology. 75:1181–1193. 2022. View Article : Google Scholar

Toffoli EC, van Vliet AA, Verheul HWM, van der Vliet HJ, Tuynman J, Spanholtz J and de Gruijl TD: Allogeneic NK cells induce monocyte-to-dendritic cell conversion, control tumor growth, and trigger a pro-inflammatory shift in patient-derived cultures of primary and metastatic colorectal cancer. J Immunother Cancer. 11:e0075542023. View Article : Google Scholar : PubMed/NCBI

Lin Y, Xu J and Lan H: Tumor-associated macrophages in tumor metastasis: Biological roles and clinical therapeutic applications. J Hematol Oncol. 12:762019. View Article : Google Scholar : PubMed/NCBI

Wang H, Wang X, Zhang X and Xu W: The promising role of tumor-associated macrophages in the treatment of cancer. Drug Resist Updat. 73:1010412024. View Article : Google Scholar : PubMed/NCBI

Hou S, Zhao Y, Chen J, Lin Y and Qi X: Tumor-associated macrophages in colorectal cancer metastasis: Molecular insights and translational perspectives. J Transl Med. 22:622024. View Article : Google Scholar : PubMed/NCBI

Dou L, Shi X, He X and Gao Y: Macrophage phenotype and function in liver disorder. Front Immunol. 10:31122019. View Article : Google Scholar

Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, et al: Macrophage activation and polarization: Nomenclature and experimental guidelines. Immunity. 41:14–20. 2014. View Article : Google Scholar : PubMed/NCBI

Wang J, Zhu N, Su X, Gao Y and Yang R: Novel tumor-associated macrophage populations and subpopulations by single cell RNA sequencing. Front Immunol. 14:12647742023. View Article : Google Scholar

Liu Y, Zhang Q, Xing B, Luo N, Gao R, Yu K, Hu X, Bu Z, Peng J, Ren X and Zhang Z: Immune phenotypic linkage between colorectal cancer and liver metastasis. Cancer Cell. 40:424–437.e5. 2022. View Article : Google Scholar : PubMed/NCBI

Matusiak M, Hickey JW, van IDGP, Lu G, Kidziński L, Zhu S, Colburg DRC, Luca B, Phillips DJ, Brubaker SW, et al: Spatially segregated macrophage populations predict distinct outcomes in colon cancer. Cancer Discov. 14:1418–1439. 2024. View Article : Google Scholar : PubMed/NCBI

Xu C, Sun L, Jiang C, Zhou H, Gu L, Liu Y and Xu Q: SPP1, analyzed by bioinformatics methods, promotes the metastasis in colorectal cancer by activating EMT pathway. Biomed Pharmacother. 91:1167–1177. 2017. View Article : Google Scholar : PubMed/NCBI

Sathe A, Mason K, Grimes SM, Zhou Z, Lau BT, Bai X, Su A, Tan X, Lee H, Suarez CJ, et al: Colorectal cancer metastases in the liver establish immunosuppressive spatial networking between tumor-sssociated SPP1+ macrophages and fibroblasts. Clin Cancer Res. 29:244–260. 2023. View Article : Google Scholar

Wu Y, Yang S, Ma J, Chen Z, Song G, Rao D, Cheng Y, Huang S, Liu Y, Jiang S, et al: Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level. Cancer Discov. 12:134–153. 2022. View Article : Google Scholar

Qi J, Sun H, Zhang Y, Wang Z, Xun Z, Li Z, Ding X, Bao R, Hong L, Jia W, et al: Single-cell and spatial analysis reveal interaction of FAP⁺ fibroblasts and SPP1⁺ macrophages in colorectal cancer. Nat Commun. 13:17422022. View Article : Google Scholar

Friedman SL: Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 88:125–172. 2008. View Article : Google Scholar : PubMed/NCBI

Nielsen SR, Quaranta V, Linford A, Emeagi P, Rainer C, Santos A, Ireland L, Sakai T, Sakai K, Kim YS, et al: Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Nat Cell Biol. 18:549–560. 2016. View Article : Google Scholar : PubMed/NCBI

Kisseleva T and Brenner D: Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 18:151–166. 2021. View Article : Google Scholar

Carloni V, Luong TV and Rombouts K: Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: More complicated than ever. Liver Int. 34:834–843. 2014. View Article : Google Scholar : PubMed/NCBI

Ali E, Trailin A, Ambrozkiewicz F, Liska V and Hemminki K: Activated hepatic stellate cells in hepatocellular carcinoma: Their role as a potential target for future therapies. Int J Mol Sci. 23:152922022. View Article : Google Scholar : PubMed/NCBI

Liu H, Qiu F, Wang Y, Zeng Q, Liu C, Chen Y, Liang CL, Zhang Q, Han L, Dai Z, et al: CD8+CD122+PD-1+ tregs synergize with costimulatory blockade of CD40/CD154, but Not B7/CD28, to prolong murine allograft survival. Front Immunol. 10:3062019. View Article : Google Scholar : PubMed/NCBI

Hsieh CC, Hung CH, Chiang M, Tsai YC and He JT: Hepatic stellate cells enhance liver cancer progression by inducing myeloid-derived suppressor cells through Interleukin-6 signaling. Int J Mol Sci. 20:50792019. View Article : Google Scholar : PubMed/NCBI

Assudani DP, Horton RB, Mathieu MG, McArdle SE and Rees RC: The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines. Cancer Immunol Immunother. 56:70–80. 2007. View Article : Google Scholar

Lee HG, Cho MJ and Choi JM: Bystander CD4+ T cells: Crossroads between innate and adaptive immunity. Exp Mol Med. 52:1255–1263. 2020. View Article : Google Scholar : PubMed/NCBI

Chalmin F, Mignot G, Bruchard M, Chevriaux A, Végran F, Hichami A, Ladoire S, Derangère V, Vincent J, Masson D, et al: Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity. 36:362–373. 2012. View Article : Google Scholar : PubMed/NCBI

Kroemer M, Turco C, Spehner L, Viot J, Idirène I, Bouard A, Renaude E, Deschamps M, Godet Y, Adotévi O, et al: Investigation of the prognostic value of CD4 T cell subsets expanded from tumor-infiltrating lymphocytes of colorectal cancer liver metastases. J Immunother Cancer. 8:e0014782020. View Article : Google Scholar : PubMed/NCBI

Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pagès F and Galon J: Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 71:1263–1271. 2011. View Article : Google Scholar : PubMed/NCBI

Farhood B, Najafi M and Mortezaee K: CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol. 234:8509–8521. 2019. View Article : Google Scholar

St Paul M and Ohashi PS: The roles of CD8⁺ T cell subsets in antitumor immunity. Trends Cell Biol. 30:695–704. 2020. View Article : Google Scholar : PubMed/NCBI

Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, Werner MT, Huang AC, Alexander KA, Wu JE, et al: TOX transcriptionally and epigenetically programs CD8⁺ T cell exhaustion. Nature. 571:211–218. 2019. View Article : Google Scholar : PubMed/NCBI

Oshi M, Asaoka M, Tokumaru Y, Yan L, Matsuyama R, Ishikawa T, Endo I and Takabe K: CD8 T cell score as a prognostic biomarker for triple negative breast cancer. Int J Mol Sci. 21:69682020. View Article : Google Scholar : PubMed/NCBI

Voskoboinik I, Whisstock JC and Trapani JA: Perforin and granzymes: Function, dysfunction and human pathology. Nat Rev Immunol. 15:388–400. 2015. View Article : Google Scholar : PubMed/NCBI

Masuda K, Kornberg A, Miller J, Lin S, Suek N, Botella T, Secener KA, Bacarella AM, Cheng L, Ingham M, et al: Multiplexed single-cell analysis reveals prognostic and nonprognostic T cell types in human colorectal cancer. JCI Insight. 7:e1546462022. View Article : Google Scholar : PubMed/NCBI

Doherty DG: Immunity, tolerance and autoimmunity in the liver: A comprehensive review. J Autoimmun. 66:60–75. 2016. View Article : Google Scholar

Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, Lynn RC, Philip M, Rao A, Restifo NP, et al: Defining 'T cell exhaustion'. Nat Rev Immunol. 19:665–674. 2019. View Article : Google Scholar : PubMed/NCBI

Freitas-Lopes MA, Mafra K, David BA, Carvalho-Gontijo R and Menezes GB: Differential location and distribution of hepatic immune cells. Cells. 6:482017. View Article : Google Scholar : PubMed/NCBI

Li H and Xia N: The multifaceted roles of B lymphocytes in metabolic dysfunction-associated steatotic liver disease. Front Immunol. 15:14473912024. View Article : Google Scholar : PubMed/NCBI

Xu Y, Wei Z, Feng M, Zhu D, Mei S, Wu Z, Feng Q, Chang W, Ji M, Liu C, et al: Tumor-infiltrated activated B cells suppress liver metastasis of colorectal cancers. Cell Rep. 40:1112952022. View Article : Google Scholar : PubMed/NCBI

Wang Y, Jia J, Wang F, Fang Y, Yang Y, Zhou Q, Yuan W, Gu X, Hu J and Yang S: Pre-metastatic niche: formation, characteristics and therapeutic implication. Signal Transduct Target Ther. 9:2362024. View Article : Google Scholar : PubMed/NCBI

Taher TE, Bystrom J, Ong VH, Isenberg DA, Renaudineau Y, Abraham DJ and Mageed RA: Intracellular B lymphocyte signalling and the regulation of humoral immunity and autoimmunity. Clin Rev Allergy Immunol. 53:237–264. 2017. View Article : Google Scholar : PubMed/NCBI

Chandnani N, Gupta I, Mandal A and Sarkar K: Participation of B cell in immunotherapy of cancer. Pathol Res Pract. 255:1551692024. View Article : Google Scholar : PubMed/NCBI

Sautes-Fridman C, Petitprez F, Calderaro J and Fridman WH: Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 19:307–325. 2019. View Article : Google Scholar : PubMed/NCBI

Fridman WH, Meylan M, Petitprez F, Sun CM, Italiano A and Sautes-Fridman C: B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol. 19:441–457. 2022. View Article : Google Scholar : PubMed/NCBI

Zhang Y, Liu G, Zeng Q, Wu W, Lei K, Zhang C, Tang M, Zhang Y, Xiang X, Tan L, et al: CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis. Cancer Cell. 42:1370–1385.e9. 2024. View Article : Google Scholar : PubMed/NCBI

Wang Z, Lu Z, Lin S, Xia J, Zhong Z, Xie Z, Xing Y, Qie J, Jiao M, Li Y, et al: Leucine-tRNA-synthase-2-expressing B cells contribute to colorectal cancer immunoevasion. Immunity. 55:1067–1081.e8. 2022. View Article : Google Scholar : PubMed/NCBI

de Ridder J, de Wilt JH, Simmer F, Overbeek L, Lemmens V and Nagtegaal I: Incidence and origin of histologically confirmed liver metastases: An explorative case-study of 23,154 patients. Oncotarget. 7:55368–55376. 2016. View Article : Google Scholar : PubMed/NCBI

Sala RJ, Ery J, Cuesta-Peredo D, Muedra V and Rodilla V: Complete blood count alterations prior to the diagnosis of colorectal cancer may help in the detection of synchronous liver metastases. J Clin Med. 12:65402023. View Article : Google Scholar : PubMed/NCBI

Zhao D, Wang L, Chen Z, Zhang L and Xu L: KRAS is a prognostic biomarker associated with diagnosis and treatment in multiple cancers. Front Genet. 13:10249202022. View Article : Google Scholar : PubMed/NCBI

Johnson D, Chee CE, Wong W, Lam RCT, Tan IBH and Ma BBY: Current advances in targeted therapy for metastatic colorectal cancer-Clinical translation and future directions. Cancer Treat Rev. 125:1027002024. View Article : Google Scholar

Sinicrope FA, Shi Q, Allegra CJ, Smyrk TC, Thibodeau SN, Goldberg RM, Meyers JP, Pogue-Geile KL, Yothers G, Sargent DJ and Alberts SR: Association of DNA mismatch repair and mutations in BRAF and KRAS with survival after recurrence in Stage III colon cancers: A secondary analysis of 2 randomized clinical trials. JAMA Oncol. 3:472–480. 2017. View Article : Google Scholar :

Kuipers EJ and Grobbee EJ: Personalised screening for colorectal cancer, ready for take-off. Gut. 69:403–404. 2020. View Article : Google Scholar

Bipat S, van Leeuwen MS, Ijzermans JN, Comans EF, Planting AS, Bossuyt PM, Greve JW and Stoker J: Evidence-base guideline on management of colorectal liver metastases in the Netherlands. Neth J Med. 65:5–14. 2007.PubMed/NCBI

Bonney GK, Chew CA, Lodge P, Hubbard J, Halazun KJ, Trunecka P, Muiesan P, Mirza DF, Isaac J, Laing RW, et al: Liver transplantation for non-resectable colorectal liver metastases: The International Hepato-Pancreato-Biliary Association consensus guidelines. Lancet Gastroenterol Hepatol. 6:933–946. 2021. View Article : Google Scholar : PubMed/NCBI

Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF and Bast RC Jr; ASCO: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 24:5313–5327. 2006. View Article : Google Scholar : PubMed/NCBI

Desch CE, Benson AB III, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, Minsky BD, Pfister DG, Virgo KS and Petrelli NJ; American Society of Clinical Oncology: Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 23:8512–8519. 2005. View Article : Google Scholar : PubMed/NCBI

Chinese College of Surgeons; Section of Gastrointestinal Surgery, Branch of Surgery, Chinese Medical Association; Section of Colorectal Surgery, Branch of Surgery, Chinese Medical Association; Colorectal Cancer Professional Committee, Chinese Anti-Cancer Association; Colorectal Cancer Professional Committee, Chinese Medical Doctor Association; Colorectal Cancer Expert Committee, Chinese Society of Clinical Oncology; Chinese Society of Colon & Rectal Surgeons, Chinese College of Surgeons, Chinese Medical Doctor Association; Metastasis Research Committee, Anorectal Branch of Chinese Medical Doctor Association; Section of Colorectal Oncology, Oncology Branch, Chinese Medical Association; Branch of Metastatic Tumor Therapy, China International Exchange and Promotive Association for Medical and Health Care; Branch of Colorectal Disease, China International Exchange and Promotive Association for Medical and Health Care: China guideline for diagnosis and comprehensive treatment of colorectal liver metastases (version 2023). Zhonghua Wei Chang Wai Ke Za Zhi. 26:1–15. 2023.In Chinese.

Adam R, de Gramont A, Figueras J, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, Sobrero A, et al: Managing synchronous liver metastases from colorectal cancer: A multid isciplinary international consensus. Cancer Treat Rev. 41:729–741. 2015. View Article : Google Scholar : PubMed/NCBI

Creasy JM, Sadot E, Koerkamp BG, Chou JF, Gonen M, Kemeny NE, Balachandran VP, Kingham TP, DeMatteo RP, Allen PJ, et al: Actual 10-year survival after hepatic resection of colorectal liver metastases: What factors preclude cure? Surgery. 163:1238–1244. 2018. View Article : Google Scholar : PubMed/NCBI

Sa Cunha A, Laurent C, Rault A, Couderc P, Rullier E and Saric J: A second liver resection due to recurrent colorectal liver metastases. Arch Surg. 142:1144–1149. 2007. View Article : Google Scholar : PubMed/NCBI

Prior TW, Leach ME and Finanger EL: Spinal Muscular Atrophy. GeneReviews(^®). Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE and Amemiya A: University of Washington; Seattle: Copyright © 1993-2025, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved., Seattle (WA). 1993

Boudjema K, Locher C, Sabbagh C, Ortega-Deballon P, Heyd B, Bachellier P, Métairie S, Paye F, Bourlier P, Adam R, et al: Simultaneous versus delayed resection for initially resectable synchronous colorectal cancer liver metastases: A prospective, open-label, randomized, controlled trial. Ann Surg. 273:49–56. 2021. View Article : Google Scholar

Ge Y, Lei S, Cai B, Gao X, Wang G, Wang L and Wang Z: Incidence and prognosis of pulmonary metastasis in colorectal cancer: A population-based study. Int J Colorectal Dis. 35:223–232. 2019. View Article : Google Scholar : PubMed/NCBI

Huo X, Zhang L and Li T: Analysis of the association of the expression of KiSS-1 in colorectal cancer tissues with the pathology and prognosis. Oncol Lett. 15:3056–3060. 2018.PubMed/NCBI

Jin LJ, Chen WB, Zhang XY, Bai J, Zhao HC and Wang ZY: Analysis of factors potentially predicting prognosis of colorectal cancer. World J Gastrointest Oncol. 11:1206–1217. 2019. View Article : Google Scholar

Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH and Diaz LA Jr: Immunotherapy in colorectal cancer: Rationale, challenges and potentia. Nat Rev Gastroenterol Hepatol. 16:361–375. 2019. View Article : Google Scholar : PubMed/NCBI

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, et al: Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 24:541–550. PubMed/NCBI

Yuan L, Tan Z, Huang J, Chen F, Hambly BD, Bao S and Tao K: Exploring the clinical significance of IL-38 correlation with PD-1, CTLA-4, and FOXP3 in colorectal cancer draining lymph nodes. Front Immunol. 15:13845482024. View Article : Google Scholar : PubMed/NCBI

Kim RD, Kovari BP, Martinez M, Xie H, Sahin IH, Mehta R, Strosberg J, Imanirad I, Ghayouri M, Kim YC, et al: A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Eur J Cancer. 169:93–102. 2022. View Article : Google Scholar : PubMed/NCBI

Saberzadeh-Ardestani B, Jones JC, Hubbard JM, McWilliams RR, Halfdanarson TR, Shi Q, Sonbol MB, Ticku J, Jin Z and Sinicrope FA: Association between survival and metastatic site in mismatch repair–deficient metastatic colorectal cancer treated with first-line pembrolizumab. JAMA Netw Open. 6:e230400. 2023. View Article : Google Scholar

Chen EX, Loree JM, Titmuss E, Jonker DJ, Kennecke HF, Berry S, Couture F, Ahmad CE, Goffin JR, Kavan P, et al: Liver metastases and immune checkpoint inhibitor efficacy in patients with refractory metastatic colorectal cancer: A secondary analysis of a randomized clinical trial. JAMA Netw Open. 6:e2346094. 2023. View Article : Google Scholar : PubMed/NCBI

Hecht JR, Raman SS, Chan A, Kalinsky K, Baurain JF, Jimenez MM, Garcia MM, Berger MD, Lauer UM, Khattak A, et al: Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases. ESMO Open. 8:1008842023. View Article : Google Scholar : PubMed/NCBI

Taïeb J, Bouche O, André T, Le Malicot K, Laurent-Puig P, Bez J, Toullec C, Borg C, Randrian V, Evesque L, et al: Avelumab vs standard second-line chemotherapy in patients with metastatic colorectal cancer and microsatellite instability: A randomized clinical trial. JAMA Oncol. 9:1356–1363. 2023. View Article : Google Scholar : PubMed/NCBI

Wang R, Lian J, Wang X, Pang X, Xu B, Tang S, Shao J and Lu H: Survival rate of colorectal cancer in China: A systematic review and meta-analysis. Front Oncol. 13:10331542023. View Article : Google Scholar : PubMed/NCBI

Saberzadeh-Ardestani B, Jones JC, Hubbard JM, McWilliams RR, Halfdanarson TR, Shi Q, Sonbol MB, Ticku J, Jin Z and Sinicrope FA: Association between survival and metastatic site in mismatch Repair-deficient metastatic colorectal cancer treated with First-line pembrolizumab. JAMA Netw Open. 6:e2304002023. View Article : Google Scholar : PubMed/NCBI

Diaz LA, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, et al: Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): Final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 23:659–670. 2022. View Article : Google Scholar : PubMed/NCBI

André T, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, et al: Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol. 33:1052–1060. 2022. View Article : Google Scholar

Del Paggio JC: Immunotherapy: Cancer immunotherapy and the value of cure. Nat Rev Clin Oncol. 15:268–270. 2018. View Article : Google Scholar : PubMed/NCBI

Kong X, Li Q, Wang D, Wang M, Yang F and Meng J: Mechanism of Qizhen decoction-mediated maturation of DC cells to activate the IL-12/JAK2/STAT4 pathway to sensitise PD-1 inhibitors in the treatment of colorectal cancer. J Ethnopharmacol. 320:1173992024. View Article : Google Scholar

Chen L, Jiang X, Li Y, Zhang Q, Li Q, Zhang X, Zhang M, Yu Q and Gao D: How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC. Clin Immunol. 237:1089622022. View Article : Google Scholar : PubMed/NCBI

Peng X, Xu Z, Guo Y and Zhu Y: Necroptosis-related genes associated with immune activity and prognosis of colorectal cancer. Front Genet. 13:9092452022. View Article : Google Scholar : PubMed/NCBI

Fan T, Zhang M, Yang J, Zhu Z, Cao W and Dong C: Therapeutic cancer vaccines: Advancements, challenges, and prospects. Signal Transduct Target Ther. 8:4502023. View Article : Google Scholar : PubMed/NCBI

Sarvizadeh M, Ghasemi F, Tavakoli F, Sadat Khatami S, Razi E, Sharifi H, Biouki NM and Taghizadeh M: Vaccines for colorectal cancer: An update. J Cell Biochem. 120:8815–8828. 2019. View Article : Google Scholar

Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika AC, et al: A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg. 258:879–886. 2013. View Article : Google Scholar : PubMed/NCBI

Rodriguez J, Castañón E, Perez-Gracia JL, Rodriguez I, Viudez A, Alfaro C, Oñate C, Perez G, Rotellar F, Inogés S, et al: A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis. J Immunother Cancer. 6:962018. View Article : Google Scholar : PubMed/NCBI

Busch DH, Fräßle SP, Sommermeyer D, Buchholz VR and Riddell SR: Role of memory T cell subsets for adoptive immunotherapy. Semin Immunol. 28:28–34. 2016. View Article : Google Scholar : PubMed/NCBI

Chan JD, Lai J, Slaney CY, Kallies A, Beavis PA and Darcy PK: Cellular networks controlling T cell persistence in adoptive cell therapy. Nat Rev Immunol. 21:769–784. 2021. View Article : Google Scholar : PubMed/NCBI

Dougé A, El Ghazzi N, Lemal R and Rouzaire P: Adoptive T cell therapy in solid tumors: State-of-the Art, current challenges, and upcoming improvements. Mol Cancer Ther. 23:272–284. 2024. View Article : Google Scholar

Chai LF, Hardaway JC, Heatherton KR, O'Connell KP, LaPorte JP, Guha P, Lopes MC, Rabinowitz BA, Jaroch D, Cox BF, et al: Antigen receptor T cells (CAR-T) effectively control tumor growth in a colorectal liver metastasis model. J Surg Res. 272:37–50. 2022. View Article : Google Scholar

Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y, Zhang R, Xiong Z, Wei Z, Shen J, et al: Phase I escalating-Dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers. Mol Ther. 25:1248–1258. 2017. View Article : Google Scholar : PubMed/NCBI

Xu J, Meng Q, Sun H, Zhang X, Yun J, Li B, Wu S, Li X, Yang H, Zhu H, et al: HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer. Cell Death Dis. 12:11092021. View Article : Google Scholar : PubMed/NCBI

Zhou X, Yang M, Yu J, Tan J, Xu N, Zhou Y, Zhang W, Ma J, Zhang Z, Friedlaender A, et al: Regional delivery of mesothelin-targeted chimeric antigen receptor T-cell effectively and safely targets colorectal cancer liver metastases in mice. J Gastrointest Oncol. 15:312–329. 2024. View Article : Google Scholar : PubMed/NCBI

Martínez Bedoya D, Dutoit V and Migliorini D: Allogeneic CAR T cells: An alternative to overcome challenges of CAR T cell therapy in glioblastoma. Front Immunol. 12:6400822021. View Article : Google Scholar : PubMed/NCBI

Pabla B, Bissonnette M and Konda VJ: Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention. World J Clin Oncol. 6:133–141. 2015. View Article : Google Scholar : PubMed/NCBI

Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009. View Article : Google Scholar : PubMed/NCBI

Christodoulou C: Reply to the reply to the letter to the editor on 'Scalp metastases and scalp cooling for chemotherapy-induced alopecia prevention', by W. P. M. Breed (doi:10.1093/annonc/mdj085). Ann Oncol. 17:7252006. View Article : Google Scholar : PubMed/NCBI

Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol. 15:1065–1075. 2014. View Article : Google Scholar : PubMed/NCBI

Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, et al: Effect of First-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS Wild-type advanced or metastatic colorectal cancer: A randomized clinical trial. JAMA. 317:2392–2401. 2017. View Article : Google Scholar : PubMed/NCBI

Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS and Go WY: PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 32:2240–2247. 2014. View Article : Google Scholar : PubMed/NCBI

Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, et al: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): A post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol. 17:1426–1434. 2016. View Article : Google Scholar : PubMed/NCBI

Khattak MA, Martin H, Davidson A and Phillips M: Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: A meta-analysis of randomized clinical trials. Clin Colorectal Cancer. 14:81–90. 2015. View Article : Google Scholar : PubMed/NCBI

Creasy JM, Sadot E, Koerkamp BG, Chou JF, Gonen M, Kemeny NE, Saltz LB, Balachandran VP, Peter Kingham T, DeMatteo RP, et al: The impact of primary tumor location on Long-term survival in patients undergoing hepatic resection for metastatic colon cancer. Ann Surg Oncol. 25:431–438. 2018. View Article : Google Scholar

Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP, Tabernero J, et al: Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 28:1713–1729. 2017. View Article : Google Scholar : PubMed/NCBI

Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ and Heinemann V: Prognostic and predictive relevance of primary tumor location in patients with RAS Wild-type metastatic colorectal cancer: Retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 3:194–201. 2017. View Article : Google Scholar

Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, Tabernero J, Douillard JY, André T and Peeters M: Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: Results from two randomized first-line panitumumab studies. Ann Oncol. 28:1862–1868. 2017. View Article : Google Scholar : PubMed/NCBI

Hecht JR, Cohn A, Dakhil S, Saleh M, Piperdi B, Cline-Burkhardt M, Tian Y and Go WY: SPIRITT: A randomized, multicenter, Phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as Second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer. Clin Colorectal Cancer. 14:72–80. 2015. View Article : Google Scholar : PubMed/NCBI

Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, et al: Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol. 25:1018–1025. 2014. View Article : Google Scholar : PubMed/NCBI

Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, Ye QH, Yu Y, Xu B, Qin XY and Xu J: Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 31:1931–1938. 2013. View Article : Google Scholar : PubMed/NCBI

Carrato A, Abad A, Massuti B, Grávalos C, Escudero P, Longo-Muñoz F, Manzano JL, Gómez A, Safont MJ, Gallego J, et al: First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). Eur J Cancer. 81:191–202. 2017. View Article : Google Scholar : PubMed/NCBI

Primrose J, Falk S, Finch-Jones M, Valle J, O'Reilly D, Siriwardena A, Hornbuckle J, Peterson M, Rees M, Iveson T, et al: Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: The New EPOC randomised controlled trial. Lancet Oncol. 15:601–611. 2014. View Article : Google Scholar : PubMed/NCBI

Bisschop C, van Dijk TH, Beukema JC, Jansen RLH, Gelderblom H, de Jong KP, Rutten HJT, van de Velde CJH, Wiggers T, Havenga K and Hospers GAP: Short-Course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical treatment in primary Stage IV rectal cancer: Long-term results of a phase II study. Ann Surg Oncol. 24:2632–2638. 2017. View Article : Google Scholar : PubMed/NCBI

Chen HH, Lin JK, Chen JB, Chuang CH, Liu MC, Wang JY and Changchien CR: Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: A phase II, open-label, single-arm, noncomparative trial. Asia Pac J Clin Oncol. 14:61–68. 2018. View Article : Google Scholar

Pietrantonio F, Cotsoglou C, Fuca G, Lo Vullo S, Nichetti F, Milione M, Coppa J, Vaiani M, Alessi A, Prisciandaro M, et al: Perioperative Bevacizumab-based triplet chemotherapy in patients with potentially resectable colorectal cancer liver metastases. Clin Colorectal Cancer. 18:34–43.e6. 2019. View Article : Google Scholar

Yasuno M, Uetake H, Ishiguro M, Mizunuma N, Komori T, Miyata G, Shiomi A, Kagimura T and Sugihara K: mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): A multicenter phase II trial comprising the final analysis for survival. Int J Clin Oncol. 24:516–525. 2019. View Article : Google Scholar : PubMed/NCBI

Takii Y, Maruyama S and Nogami H: Can the prognosis of colorectal cancer be improved by surgery? World J Gastrointest Surg. 8:574–577. 2016. View Article : Google Scholar : PubMed/NCBI

Zhou F and Ding J: Prognosis and factors affecting colorectal cancer with ovarian metastasis. Updates Surg. 73:391–398. 2021. View Article : Google Scholar : PubMed/NCBI

Ramdhani K, Smits MLJ, Lam MGEH and Braat AJAT: Combining selective internal radiation therapy with immunotherapy in treating hepatocellular carcinoma and hepatic colorectal metastases: A systematic review. Cancer Biother Radiopharm. 38:216–224. 2023.PubMed/NCBI

Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, et al: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 27:1386–1422. PubMed/NCBI

Azeredo-da-Silva ALF, de Jesus VHF, Agirrezabal I, Brennan VK, Carion PL, Amoury N, Vetromilla BM, Zanotto BS, Shergill S and Ziegelmann PK: Selective internal radiation therapy using Y-90 resin microspheres for metastatic colorectal cancer: An updated systematic review and network Meta-analysis. Adv Ther. 41:1606–1620. 2024. View Article : Google Scholar : PubMed/NCBI

Zhu Y, Yu J, Zhang K, Feng Y, Guo K, Sun L and Ruan S: Network pharmacology analysis to explore the pharmacological mechanism of effective Chinese medicines in treating metastatic colorectal cancer using Meta-analysis approach. Am J Chin Med. 49:1839–1870. PubMed/NCBI

Lam W, Bussom S, Guan F, Jiang Z, Zhang W, Gullen EA, Liu SH and Cheng YC: The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med. 2:45ra592010. View Article : Google Scholar : PubMed/NCBI

Sun Q, He M, Zhang M, Zeng S, Chen L, Zhao H, Yang H, Liu M, Ren S and Xu H: Traditional Chinese medicine and colorectal cancer: Implications for drug discovery. Front Pharmacol. 12:6850022021. View Article : Google Scholar : PubMed/NCBI

Liu N, Wu C, Jia R, Cai G, Wang Y, Zhou L, Ji Q, Sui H, Zeng P, Xiao H, et al: Traditional Chinese medicine combined with chemotherapy and cetuximab or bevacizumab for metastatic colorectal cancer: A randomized, double-blind, Placebo-controlled clinical trial. Front Pharmacol. 11:4782020. View Article : Google Scholar : PubMed/NCBI

Zhang T, He WT, Zi MJ, Song G, Yi DH and Yang YF: Cohort study on prognosis of patients with metastatic colorectal cancer treated with integrated Chinese and Western medicine. Chin J Integr Med. 24:573–578. 2018. View Article : Google Scholar : PubMed/NCBI

Tang M, Zhang W, Qin W, Zou C, Yan Y, He B, Xu Y, Zhang Y, Liu J, Sun H and Yang Y: Association between Oral Chinese herbal medicine and recurrence and metastasis in patients with stages II and III colorectal cancer: A cohort study in China. Evid Based Complement Alternat Med. 2022:85293952022. View Article : Google Scholar : PubMed/NCBI

Hsiao WL and Liu L: The role of traditional Chinese herbal medicines in cancer therapy-from TCM theory to mechanistic insights. Planta Med. 76:1118–1131. 2010. View Article : Google Scholar : PubMed/NCBI

Rodrigues JA and Correia JH: Photodynamic therapy for colorectal cancer: An update and a look to the future. Int J Mol Sci. 24:122042023. View Article : Google Scholar : PubMed/NCBI

van Duijnhoven FH, Rovers JP, Engelmann K, Krajina Z, Purkiss SF, Zoetmulder FA, Vogl TJ and Terpstra OT: Photodynamic therapy with 5,10,15, 20 -Tetrak is (m-Hydroxyphenyl) bacteriochlorin for colorectal liver metastases is safe and feasible: Results from a phase I study. Ann Surg Oncol. 12:808–816. 2005. View Article : Google Scholar : PubMed/NCBI

Gu B, Wang B, Li X, Feng Z, Ma C, Gao L, Yu Y, Zhang J, Zheng P, Wang Y, et al: Photodynamic therapy improves the clinical efficacy of advanced colorectal cancer and recruits immune cells into the tumor immune microenvironment. Front Immunol. 13:10504212022. View Article : Google Scholar : PubMed/NCBI

Hao Y, Gu Z, Yu Z, Schomann T, Sayedipour S, Aguilar JC, Ten Dijke P and Cruz LJ: Photodynamic therapy in combination with the hepatitis B core virus-like particles (HBc VLPs) to prime anticancer immunity for colorectal cancer treatment. Cancers (Basel). 14:27242022. View Article : Google Scholar : PubMed/NCBI

Liang X, Chen M, Bhattarai P, Hameed S and Dai Z: Perfluorocarbon@Porphyrin nanoparticles for tumor hypoxia relief to enhance photodynamic therapy against liver metastasis of colon cancer. ACS Nano. 14:13569–13583. 2020. View Article : Google Scholar : PubMed/NCBI